Understanding Gastroparesis Linked to Ozempic Use

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Specific Risk Awareness

If you're experiencing persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be wondering about gastroparesis—a condition where stomach emptying slows. Building on decades of medical research into drug side effects, this page explains how doctors test for and evaluate gastroparesis in the context of Ozempic use, so you can understand the diagnostic process.

Understanding Ozempic and Gastroparesis: A Medical Overview

Ozempic, a glucagon-like peptide-1 (GLP-1) receptor agonist approved for type 2 diabetes, has been associated with a range of gastrointestinal adverse effects, including gastroparesis. Gastroparesis is a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, abdominal pain, and early satiety. The clinical presentation of gastroparesis can vary, but it often involves chronic or recurrent upper gastrointestinal symptoms that may significantly impair quality of life. Diagnosis typically relies on gastric emptying scintigraphy or other motility studies, along with exclusion of other causes. The pharmacology of Ozempic (semaglutide) involves activation of GLP-1 receptors, which slows gastric emptying as part of its mechanism to reduce postprandial glucose excursions. However, this effect can become pathological in some patients, leading to gastroparesis. Mechanistically, GLP-1 receptor agonists like Ozempic inhibit gastric motility by acting on vagal afferent nerves and directly on smooth muscle cells, potentially causing sustained delays in gastric emptying. This pathway is supported by clinical trial data showing that gastrointestinal adverse reactions occur more frequently with Ozempic than placebo. In placebo-controlled trials, gastrointestinal adverse reactions occurred in 32.7% of patients receiving Ozempic 0.5 mg and 36.4% of those receiving 1 mg, compared to 15.3% in the placebo group (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Discontinuation due to these reactions was also higher: 3.1% for 0.5 mg and 3.8% for 1 mg, versus 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing 1 mg and 2 mg doses, gastrointestinal adverse reactions occurred in 30.8% and 34.0% of patients, respectively (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (1.9% placebo, 3.5% at 0.5 mg, 2.7% at 1 mg), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these are not explicitly labeled as gastroparesis, they are consistent with symptoms of delayed gastric emptying. Post-marketing surveillance data from the FDA Adverse Event Reporting System (FAERS) further highlight the association. Among adverse events reported for Ozempic, "impaired gastric emptying" appears with 2,693 reports, alongside nausea (8,652 reports), vomiting (5,578 reports), and diarrhea (5,274 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). This suggests that gastroparesis is a recognized adverse event in clinical practice.

Legal Considerations for Ozempic-Related Gastroparesis

Regarding the adequacy of warnings, the Ozempic prescribing information includes gastrointestinal adverse reactions in the label, but it does not specifically mention gastroparesis as a distinct warning. The label notes that nausea, vomiting, and diarrhea are common, particularly during dose escalation, and that discontinuation may be necessary. However, the absence of a specific warning for gastroparesis may leave patients and healthcare providers unaware of the potential for this serious condition. For affected patients, this raises questions about whether the risks were adequately communicated. Attorney-related considerations for patients who develop gastroparesis after using Ozempic include evaluating whether the manufacturer provided sufficient warnings about the risk of delayed gastric emptying. The timeline between exposure and documented harm is critical; gastroparesis symptoms often emerge during dose escalation or after prolonged use, as suggested by the higher incidence of gastrointestinal reactions at higher doses. Patients who experience persistent symptoms should seek medical evaluation and document the onset relative to Ozempic initiation. In summary, the evidence indicates a plausible mechanistic link between Ozempic and gastroparesis, supported by clinical trial data showing increased gastrointestinal adverse reactions and post-marketing reports of impaired gastric emptying. The adequacy of warnings is questionable, as the label does not explicitly address gastroparesis. Patients affected by this condition may benefit from consulting with an attorney to explore legal options, particularly if they experienced severe or prolonged symptoms without adequate prior warning.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it linked to Ozempic?

Gastroparesis is a condition characterized by delayed gastric emptying, causing symptoms like nausea, vomiting, and abdominal pain. Ozempic, a GLP-1 receptor agonist, slows gastric emptying as part of its mechanism, which can become pathological in some patients, leading to gastroparesis. Clinical trials show higher rates of gastrointestinal adverse reactions with Ozempic compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does the Ozempic label warn about gastroparesis?

The Ozempic prescribing information includes gastrointestinal adverse reactions like nausea and vomiting but does not specifically mention gastroparesis as a distinct warning. This lack of explicit warning may leave patients unaware of the potential for this serious condition.

What legal options do I have if I developed gastroparesis from Ozempic?

If you developed gastroparesis after using Ozempic, you may have legal options based on inadequate warnings. An attorney can evaluate whether the manufacturer failed to adequately communicate the risk of delayed gastric emptying. It is important to document your symptoms and their onset relative to Ozempic use.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.